BY: Zoë LaRock
Denmark-based pharma titan Novo Nordisk struck a deal with Noom — a digital therapeutics startup known for its mobile weight management platform that utilizes a cognitive behavioral approach — to implement digital therapies for obesity, according to a press release shared with Business Insider Intelligence.
The tie-up was announced at the culmination of an eight-month trial that combined Novo Nordisk’s expertise with Noom’s digital platform. Now, the two are moving beyond a pilot phase with the goal of making their weight management solutions available to US consumers.
Partnering with a big-name pharma company affords Noom access to industry expertise and a wider pool of consumers. Noom CEO and Cofounder Saeju Jeong told Business Insider Intelligence that the tie-up with Novo Nordisk could help the startup drive better results for its customers. And collaborating with an entrenched leader in chronic disease treatment could open the doors for Noom to get its platform into the hands of more patients.